CD19 and acute lymphoblastic leukemia: Moreover, this first-in-human clinical study, conducted in patients with R/R B-ALL in China, showed that CD19-directed GC007F cell therapy were effective in eliminating CD19 positive B-ALL with a manageable toxicity.